Literature DB >> 9789529

Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma.

B Horowitz1, A Lazo, H Grossberg, G Page, A Lippin, G Swan.   

Abstract

Solvent/Detergent (SD) is an extraordinarily effective means for eliminating enveloped viruses from plasma and plasma products. The safety margin suggested by the rapid and complete kill of enveloped viruses observed in the laboratory has been confirmed repeatedly by groups worldwide and by thirteen years of routine clinical use encompassing an estimated 35 million doses of a wide variety of products. Throughout this time, there has not been a single documented case of enveloped virus transmission by an SD-treated product. This record of safety spawned the development of SD-treated plasma as a substitute for fresh frozen plasma (FFP) and has encouraged the adoption of SD for the treatment of non-blood products such as monoclonal antibodies and those derived from recombinant DNA procedures. This review summarizes the use of SD treatment, including its use in combination with other viral elimination procedures, and also summarizes Vitex's initial experience in the manufacture of SD-Plasma, recently licensed by the U.S. FDA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9789529     DOI: 10.1111/j.1423-0410.1998.tb05473.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  9 in total

1.  Plasma, guidelines, and evidence-based medicine.

Authors:  Roberto Reverberi
Journal:  Blood Transfus       Date:  2008-01       Impact factor: 3.443

2.  Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma.

Authors:  Giancarlo Maria Liumbruno; Maria Laura Sodini; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2008-01       Impact factor: 3.443

3.  The Use of Solvent/Detergent Treatment in Pathogen Reduction of Plasma.

Authors:  Peter Hellstern; Bjarte G Solheim
Journal:  Transfus Med Hemother       Date:  2011-01-17       Impact factor: 3.747

Review 4.  Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.

Authors:  Americo Cicchetti; Alexandra Berrino; Marina Casini; Paola Codella; Giuseppina Facco; Alessandra Fiore; Giuseppe Marano; Marco Marchetti; Emanuela Midolo; Roberta Minacori; Pietro Refolo; Federica Romano; Matteo Ruggeri; Dario Sacchini; Antonio G Spagnolo; Irene Urbina; Stefania Vaglio; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2016-07       Impact factor: 3.443

5.  Maturation of the Gag core decreases the stability of retroviral lipid membranes.

Authors:  Candice Davidoff; Riley J Payne; Sharon H Willis; Benjamin J Doranz; Joseph B Rucker
Journal:  Virology       Date:  2012-09-17       Impact factor: 3.616

6.  Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery.

Authors:  Stein Tølløfsrud; Harald Noddeland; Jan Ludvig Svennevig; Gunnar Bentsen; Tom Eirik Mollnes; Bjarte G Solheim
Journal:  Intensive Care Med       Date:  2003-09-04       Impact factor: 17.440

7.  TnBP⁄Triton X-45 treatment of plasma for transfusion efficiently inactivates hepatitis C virus.

Authors:  Ming-Li Chou; Thierry Burnouf; Shun-Pang Chang; Ting-Chun Hung; Chun-Ching Lin; Christopher D Richardson; Liang-Tzung Lin
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

Review 8.  Pathogen inactivation techniques.

Authors:  J P R Pelletier; S Transue; E L Snyder
Journal:  Best Pract Res Clin Haematol       Date:  2006       Impact factor: 3.020

9.  SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation.

Authors:  H F Rabenau; L Biesert; T Schmidt; G Bauer; J Cinatl; H W Doerr
Journal:  Biologicals       Date:  2005-04-07       Impact factor: 1.856

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.